Immodin to influence immunoparalysis, MODS and sepsis course in long term ICU patients
Project goals
Hypothesis is tested that imunostimulatory drug Immodin reverses immunoparalysis in critically ill patients requiring long term intensive care. Hypothesis is tested that reversal of immunoparalysis will positively influence the course of multiorgan dysfunction syndrome and sepsis in long term ICU patients. Hypothesis is tested that reversal of immunoparalysis will positively influence the course of multiorgan dysfunction syndrome and sepsis in long term ICU patients.
Keywords
intensiveimmunoparalysisimmunostimulationMODSsepsiscytomegalovirusoutcome
Public support
Provider
Ministry of Health
Programme
Branch programm of research of the Ministry of Health
Call for proposals
VaV pro Ministerstvo zdravotnictví 1 (SMZ02004NR)
Main participants
—
Contest type
VS - Public tender
Contract ID
—
Alternative language
Project name in Czech
Immodin k ovlivnění průběhu imunoparalýzy, multiorgánového selhávání (MODS) a sepse a u kriticky nemocných vyžadujících dlouhodobou intenzivní péči
Annotation in Czech
Je testována hypotéza, že podáváním imunostimulans Immodinu obnovíme reaktivitu imunitního systému u kriticky nemocných vyžadujících dlouhodobou intenzivní péči. Je testována hypotéza, že navození imunoreaktivity povede k příznivému vývoji multiorgánového selhávání a sepse u kriticky nemocných vyžadujících dlouhodobou intenzivní péči.
Scientific branches
R&D category
NV - Nonindustrial research (Applied research excluded Industrial research)
CEP classification - main branch
FN - Epidemiology, infection diseases and clinical immunology
CEP - secondary branch
FP - Other medical fields
CEP - another secondary branch
—
30106 - Anatomy and morphology (plant science to be 1.6)
30107 - Medicinal chemistry
30108 - Toxicology
30109 - Pathology
30221 - Critical care medicine and Emergency medicine
30223 - Anaesthesiology
30224 - Radiology, nuclear medicine and medical imaging
30225 - Allergy
30226 - Rheumatology
30227 - Geriatrics and gerontology
30229 - Integrative and complementary medicine (alternative practice systems)
30230 - Other clinical medicine subjects
30302 - Epidemiology
30303 - Infectious Diseases
30307 - Nursing
30308 - Nutrition, Dietetics
30309 - Tropical medicine
30310 - Parasitology
30311 - Medical ethics
30312 - Substance abuse
30501 - Forensic science
30502 - Other medical science
Completed project evaluation
Provider evaluation
U - Uspěl podle zadání (s publikovanými či patentovanými výsledky atd.)
Project results evaluation
Immodin does not influence outcome, ICU stay, nosocomial infection, sepsis and SIRS, MODS, immunologic and inflammatory markers in critically ill with immunoparalysis. Monocyte activation (CD14+HLADR+) does not predict ICU mortality.
Solution timeline
Realization period - beginning
Jan 1, 2004
Realization period - end
Jan 1, 2006
Project status
U - Finished project
Latest support payment
—
Data delivery to CEP
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data delivery code
CEP07-MZ0-NR-U/06:2
Data delivery date
Aug 8, 2007
Finance
Total approved costs
3,152 thou. CZK
Public financial support
3,152 thou. CZK
Other public sources
0 thou. CZK
Non public and foreign sources
0 thou. CZK
Recognised costs
3 152 CZK thou.
Public support
3 152 CZK thou.
0%
Provider
Ministry of Health
CEP
FN - Epidemiology, infection diseases and clinical immunology
Solution period
01. 01. 2004 - 01. 01. 2006